质子再照射治疗既往乳腺照射后的复发或新发原发性乳腺癌
中位随访21个月,无局部或区域复发,2年无远处转移生存率和总生存率分别为92.0%和93.6%,未观察到4-5级毒性。
要点
- 质子再照射后无局部或区域复发,2年DMFS为92.0%,OS为93.6%。
- 无4-5级急性或晚期毒性,但重建患者中69.2%出现包膜挛缩。
- BMI升高与≥2级急性毒性风险降低相关(OR=0.84,95%CI 0.70-1.00)。
核心结论
- 质子束再照射对于既往乳腺或胸壁放疗后的复发或新发原发性乳腺癌,可能是一种相对安全且高效的挽救治疗选择。
主要发现
- 中位首次放疗剂量为60 Gy(范围45-66 Gy),中位再照射剂量为50.4 Gy(RBE)(范围40-66.6 Gy(RBE)),中位累积剂量为110 Gy(RBE)(范围96.6-169.4 Gy(RBE))。
- 中位随访21个月,无局部或区域复发,17%的患者出现远处复发。
- 2年无远处转移生存率为92.0%,总生存率为93.6%。
- 13例接受植入物或皮瓣重建的患者中,9例(69.2%)出现包膜挛缩,其中3例(23.1%)需要手术干预。
- 1例(7.7%)患者在保乳手术后出现需要乳房切除的3级乳房疼痛;未观察到4-5级急性或晚期毒性。
临床怎么用
- 对于既往接受过乳腺或胸壁放疗的复发或新发非转移性乳腺癌患者,质子束再照射可作为挽救性放疗的考虑选项。
- 再照射前应充分评估重建情况,因包膜挛缩发生率较高且部分需手术干预。
局限性
- 需要更多患者和更长随访,以将复合正常组织剂量与毒性相关联并评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Late local recurrences and second primary breast cancers are increasingly common. Proton beam therapy (PBT) reirradiation (reRT) may allow safer delivery of a second definitive radiotherapy (RT) course. We analyzed outcomes of patients with recurrent or new primary breast cancer who underwent reRT. MATERIALS AND METHODS: In an IRB-approved retrospective study, patient/tumor characteristics, treatment parameters, outcomes, and toxicities were collected for all consecutive patients with recurrent or new primary non-metastatic breast cancer previously treated with breast or chest wall RT who underwent PBT reRT. RESULTS: Forty-six patients received reRT using uniform (70%) or pencil beam (30%) scanning PBT. Median first RT, reRT, and cumulative doses were 60 Gy (range 45-66 Gy), 50.4 Gy(RBE) (40-66.6 Gy(RBE)), and 110 Gy(RBE) (96.6-169.4 Gy(RBE)), respectively. Median follow-up was 21 months. There were no local or regional recurrences; 17% developed distant recurrence. Two-year DMFS and OS were 92.0% and 93.6%, respectively. Nine of 13 (69.2%) patients who underwent implant or flap reconstruction developed capsular contracture, 3 (23.1%) requiring surgical intervention. One (7.7%) patient developed grade 3 breast pain requiring mastectomy after breast conserving surgery. No acute or late grade 4-5 toxicities were seen. Increased body mass index (BMI) was protective of grade ≥ 2 acute toxicity (OR = 0.84, 95%CI = 0.70-1.00). CONCLUSION: In the largest series to date of PBT reRT for breast cancer recurrence or new primary after prior definitive breast or chest wall RT, excellent locoregional control and few high-grade toxicities were encountered. PBT reRT may provide a relatively safe and highly effective salvage option. Additional patients and follow-up are needed to correlate composite normal tissue doses with toxicities and assess long-term outcomes.
引用
- Choi JI, Khan AJ, Powell SN, et al. Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation. Radiother Oncol. 2021. PMID: 34688807. doi:10.1016/j.radonc.2021.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。